|
a) SNPs associated with anti-HCV status
|
|---|
|
Genotype
|
Uninfected N(%)
|
Infected N(%)
|
OR (95% CI)
|
P value
|
|---|
|
rs1063478
| | | | |
|
CC
|
223 (46.3%)
|
373 (51.4%)
|
1.00
| |
|
CT
|
216 (44.8%)
|
297 (41.0%)
|
0.75 (0.56–0.99)
|
0.049
|
|
TT
|
43 (8.9%)
|
55 (7.6%)
|
0.72 (0.43–1.20)
|
0.210
|
|
Dominant
| | |
0.74 (0.56–0.98)
|
0.035
|
|
Recessive
| | |
0.83 (0.50–1.35)
|
0.444
|
|
Additive
| | |
0.81 (0.65–0.99)
|
0.049
|
|
rs2284191
| | | | |
|
GG
|
395 (82.0%)
|
572 (78.9%)
|
1.00
| |
|
AG
|
81 (16.8%)
|
146 (20.1%)
|
1.45 (1.01–2.07)
|
0.430
|
|
AA
|
6 (1.2%)
|
7 (1.0%)
|
1.32 (0.32–5.83)
|
0.701
|
|
Dominant
| | |
1.44 (1.01–2.05)
|
0.041
|
|
Recessive
| | |
1.23 (0.30–5.00)
|
0.772
|
|
Additive
| | |
1.38 (1.00–1.92)
|
0.050
|
|
rs11244
| | | | |
|
CC
|
288 (62.4%)
|
430 (63.1%)
|
1.00
| |
|
CT
|
147 (31.8%)
|
211 (21.6%)
|
1.14 (0.83–1.55)
|
0.416
|
|
TT
|
27 (5.8%)
|
40 (5.9%)
|
1.97 (1.06–3.65)
|
0.033
|
|
Dominant
| | |
1.12 (0.84–1.50)
|
0.426
|
|
Recessive
| | |
1.74 (0.95–3.18)
|
0.073
|
|
Additive
| | |
1.26 (1.00–1.60)
|
0.053
|
|
b) SNPs associated with HCV chronicity
|
|
Genotype
|
Resolver N(%)
|
Chronic N(%)
|
OR (95% CI)
|
P
value
|
|
rs17587
| | | | |
|
GG
|
123 (63.7%)
|
361 (67.9%)
|
1.00
| |
|
AG
|
58 (30.1%)
|
158 (29.8%)
|
0.94 (0.65–136)
|
0.745
|
|
AA
|
12 (6.2%)
|
12 (2.3%)
|
0.32 (0.14–0.75)
|
0.009
|
|
Dominant
| | |
0.83 (0.58–1.18)
|
0.303
|
|
Recessive
| | |
0.33 (0.14–0.76)
|
0.009
|
|
Additive
| | |
0.76 (0.57–1.03)
|
0.077
|
|
rs2071543
| | | | |
|
CC
|
125 (64.7%)
|
356 (66.9%)
|
1.00
| |
|
AC
|
54 (28.0%)
|
157 (29.5%)
|
1.06 (0.73–1.55)
|
0.756
|
|
AA
|
14 (7.3%)
|
19 (3.6%)
|
0.49 (0.24–1.02)
|
0.058
|
|
Dominant
| | |
0.94 (0.66–1.34)
|
0.749
|
|
Recessive
| | |
0.48 (0.24–0.99)
|
0.049
|
|
Additive
| | |
0.86 (0.65–1.15)
|
0.318
|
|
rs2284191
| | | | |
|
GG
|
142 (73.6%)
|
430 (80.3%)
|
1.00
| |
|
AG
|
50 (25.9%)
|
96 (18.1%)
|
0.59 (0.40, 0.88)
|
0.010
|
|
AA
|
1 (0.5%)
|
6 (1.1%)
|
1.41 (0.15, 12.89)
|
0.760
|
|
Genotype
|
Resolver N(%)
|
Chronic N(%)
|
OR (95% CI)
|
P
value
|
|
Dominant
| | |
0.61 (0.41, 0.90)
|
0.014
|
|
Recessive
| | |
1.59 (0.17, 14.43)
|
0.683
|
|
Additive
| | |
0.65 (0.45, 0.95)
|
0.240
|
|
rs376892
| | | | |
|
CC
|
109 (56.5%)
|
321 (60.3%)
|
1.00
| |
|
CT
|
81 (42.0%)
|
183 (34.4%)
|
0.67 (0.54–1.07)
|
0.112
|
|
TT
|
3 (1.5%)
|
28 (5.3%)
|
3.15 (0.93–10.64)
|
0.065
|
|
Dominant
| | |
0.84 (0.60–1.18)
|
0.317
|
|
Recessive
| | |
3.51 (1.04–11.77)
|
0.042
|
|
Additive
| | |
0.98 (0.74–1.32)
|
0.918
|
|
rs416622
| | | | |
|
GG
|
66 (34.2%)
|
242 (45.5%)
|
1.00
| |
|
AG
|
105 (54.4%)
|
216 (40.6%)
|
0.51 (0.35–0.74)
|
<0.001
|
|
AA
|
22 (11.4%)
|
74 (13.9%)
|
0.91 (0.52–1.59)
|
0.739
|
|
Dominant
| | |
0.58 (0.41–0.83)
|
0.003
|
|
Recessive
| | |
1.31 (0.78–2.19)
|
0.300
|
|
Additive
| | |
0.82 (0.64–1.04)
|
0.102
|
|
rs7383287
| | | | |
|
AA
|
125 (64.8%)
|
391 (73.5%)
|
1.00
| |
|
AG
|
25 (13.0%)
|
67 (12.6%)
|
0.84 (0.50–1.39)
|
0.495
|
|
GG
|
43 (22.2%)
|
74 (13.9%)
|
0.54 (0.35–0.85)
|
0.008
|
|
Dominant
| | |
0.66 (0.46–0.95)
|
0.025
|
|
Recessive
| | |
0.56 (0.36–0.87)
|
0.001
|
|
Additive
| | |
0.75 (0.60–0.93)
|
0.001
|
- Logistic regression analyses adjusted for age, gender, experience of blood/plasma donation, and numbers of blood/plasma donation.
